Intestinal Research

Anne G Tuskey

1 Article

Inflammatory bowel diseases

Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study: Jingzhou Wang, Takahiro I Nakamura, Anne G Tuskey, Brian W Behm; Intest Res 2019;17(4):496-503. Published online October 14, 2019; DOI: https://doi.org/10.5217/ir.2019.00050

Background/Aims
Polypharmacy is a common clinical problem with chronic diseases that can be associated with adverse patient outcomes. The present study aimed to determine the prevalence and patient-specific characteristics associated with polypharmacy in an ulcerative colitis (UC) population and to assess the impact of polypharmacy on disease outcomes.
Methods
A retrospective chart review of patients with UC who visited a tertiary medical center outpatient clinic between 2006 and 2011 was performed. Polypharmacy was defined as major ( ≥ 5 non-UC medications) or minor (2–4 non-UC medications). UC medications were excluded in the polypharmacy grouping to minimize the confounding between disease severity and polypharmacy. Outcomes of interest include disease flare, therapy escalation, UC-related hospitalization, and surgery within 5 years of the initial visit.
Results
A total of 457 patients with UC were eligible for baseline analysis. Major polypharmacy was identified in 29.8% of patients, and minor polypharmacy was identified in 40.9% of the population. Polypharmacy at baseline was associated with advanced age (P< 0.001), female sex (P= 0.019), functional gastrointestinal (GI) disorders (P< 0.001), and psychiatric disease (P< 0.001). Over 5 years of follow-up, 265 patients remained eligible for analysis. After adjusting for age, sex, functional GI disorders, and psychiatric disease, major polypharmacy was found to be significantly associated with an increased risk of disease flare (odds ratio, 4.00; 95% confidence interval, 1.66–9.62). However, major polypharmacy was not associated with the risk of therapy escalation, hospitalization, or surgery.
Conclusions
Polypharmacy from non-inflammatory bowel disease medications was present in a substantial proportion of adult patients with UC and was associated with an increased risk of disease flare.

Citations

Citations to this article as recorded by

Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets
Ekaterina Safroneeva, Helen Thorne, Ortrud Gerstner, Raphaël Laoun
Inflammatory Bowel Diseases.2025; 31(4): 975. CrossRef
Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease
Darren Drittel, William Schreiber-Stainthorp, Olivia Delau, Sakteesh V. Gurunathan, Joshua Chodosh, Dorry L. Segev, Mara McAdams-DeMarco, Seymour Katz, John Dodson, Aasma Shaukat, Adam S. Faye
American Journal of Gastroenterology.2025; 120(4): 844. CrossRef
The liver as a central “hub” of the immune system: pathophysiological implications
Vincenzo Ronca, Alessio Gerussi, Paul Collins, Alessandro Parente, Ye Htun Oo, Pietro Invernizzi
Physiological Reviews.2025; 105(2): 493. CrossRef
Modifiable Factors Influencing Disease Flares in Inflammatory Bowel Disease: A Literature Overview of Lifestyle, Psychological, and Environmental Risk Factors
Lola J. M. Koppelman, Aroha A. Oyugi, P. W. Jeroen Maljaars, Andrea E. van der Meulen-de Jong
Journal of Clinical Medicine.2025; 14(7): 2296. CrossRef
In vitro safety signals for potential clinical development of the anti-inflammatory pregnane X receptor agonist FKK6
Zdeněk Dvořák, Barbora Vyhlídalová, Petra Pečinková, Hao Li, Pavel Anzenbacher, Alena Špičáková, Eva Anzenbacherová, Vimanda Chow, Jiabao Liu, Henry Krause, Derek Wilson, Tibor Berés, Petr Tarkowski, Dajun Chen, Sridhar Mani
Bioorganic Chemistry.2024; 144: 107137. CrossRef
A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel disease
Sivan Harnik, Bella Ungar, Ronen Loebstein, Shomron Ben‐Horin
United European Gastroenterology Journal.2024; 12(5): 627. CrossRef
Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef
Factors contributing to flares of ulcerative colitis in North India- a case-control study
Vishavdeep Singh Rana, Gaurav Mahajan, Amol N. Patil, Anupam K. Singh, Vaneet Jearth, Aravind Sekar, Harjeet Singh, Atul Saroch, Usha Dutta, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
Worldwide Prevalence of Polypharmacy: A Systematic Review
Beatriz Dias Januário, Natália Silva Mafra, Humberto de Souza Silva, Isabella Monteiro Carvalho, Ana Luiza Sobreira Sena, Ana Paula Gomes Soares Pereira, Newton Santos de Faria Júnior, Helton Oliveira Campos
Current Drug Metabolism.2023; 24(8): 568. CrossRef
Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease
Vera E.R. Asscher, Sanne N. Waars, Andrea E. van der Meulen-de Jong, Rogier J.L. Stuyt, A. Martine C. Baven-Pronk, Sander van der Marel, Rutger J. Jacobs, Jeoffrey J.L. Haans, Lennart J. Meijer, Jacqueline D. Klijnsma-Slagboom, Marijn H. Duin, Milou E.R.
Clinical Gastroenterology and Hepatology.2022; 20(5): e1006. CrossRef
Health Care Costs and Resource Utilization Among Patients With Crohn’s Disease With and Without Perianal Fistula
Grace Chen, Vasantha Pedarla, Kyle D Null, Susan E Cazzetta, Qasim Rana Khan, David A Schwartz
Inflammatory Bowel Diseases.2022; 28(6): 870. CrossRef
The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis
Bharati Kochar, Nneka N. Ufere, Christine S. Ritchie, Jennifer C. Lai
Clinical and Translational Gastroenterology.2022; 13(1): e00445. CrossRef
Polypharmacy in Patients With Inflammatory Bowel Disease
Francisco Mesonero, Cristina Fernández, Eugenia Sánchez-Rodríguez, Ana García-García Paredes, Carla Senosiain, Agustín Albillos, Antonio López-Sanromán
Journal of Clinical Gastroenterology.2022; 56(3): e189. CrossRef
Is it time to include older adults in inflammatory bowel disease trials? A call for action
Sophie Vieujean, Bénédicte Caron, Vipul Jairath, Athanase Benetos, Silvio Danese, Edouard Louis, Laurent Peyrin-Biroulet
The Lancet Healthy Longevity.2022; 3(5): e356. CrossRef
Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases – A Systematic Review and Meta-Analysis
Laura Arp, Sabine Jansson, Vibeke Wewer, Johan Burisch
Journal of Crohn's and Colitis.2022; 16(12): 1933. CrossRef
Impact of isotretinoin on inflammatory bowel disease flare in patients with preexisting inflammatory bowel disease diagnosis: A cross-sectional study
Christina G. Lopez, Ruby Kwak, Lindsay McCormack, Guohai Zhou, Alexandra Charrow
Journal of the American Academy of Dermatology.2022; 87(6): 1399. CrossRef
Systematic review with meta‐analysis: dietary intake in adults with inflammatory bowel disease
Kelly Lambert, Daniel Pappas, Chiara Miglioretto, Arefeh Javadpour, Hannah Reveley, Laura Frank, Michael C. Grimm, Dorit Samocha‐Bonet, Georgina L. Hold
Alimentary Pharmacology & Therapeutics.2021; 54(6): 742. CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
Frailty in inflammatory bowel diseases: an emerging concept
Bharati Kochar, Ariela R. Orkaby, Ashwin N. Ananthakrishnan, Christine S. Ritchie
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
Jongwook Yu, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Gut and Liver.2021; 15(6): 858. CrossRef
Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions
Vanessa DeClercq, Jacob T. Nearing, Morgan G. I. Langille, Jonathan Jacobs
PLOS ONE.2021; 16(12): e0261032. CrossRef

7,811 View
184 Download
21 Web of Science
21 Crossref

Author index